Headquartered in Durban, South Africa, we are a global specialty and branded pharmaceutical company, improving the health of patients across the world through our high quality and affordable medicines. Active at every stage of the value chain, we are uniquely diversiﬁed by geography, product and manufacturing capability.
With an acknowledged presence of more than two decades in the pharmaceutical sector, we improve the health of patients in more than 150 countries. The Group’s key business segments are Manufacturing and Commercial Pharmaceuticals comprising Regional Brands and Sterile Focus Brands.
August 2022 Annual results SENS announcement
September 2022 Annual results presentation
September 2022 13th Annual RMB Morgan Stanley Big Five Investor Conference
December 2022 Annual General Meeting
Africa Middle East
This region represents the single largest revenue contributor in the Commercial Pharmaceuticals segment, with revenues predominantly from Regional Brands. Aspen supplies well-established local brands, as well as internationally recognised medicines across multiple countries in the region, supported by commercial and sales employees. Extensive and differentiated manufacturing capabilities including high potency and hormonal solids, vaccines and other state-of-the-art sterile capabilities exist at one of the Group’s primary manufacturing sites in Gqeberha, South Africa. This primary site is complemented by five regional sites across the continent.
Kingdom of Saudi Arabia
The South African private pharmaceutical sector was valued at R49,8 billion MAT* for the period ended July 2021.
In South Africa, four out of the top 15 brands in the private sector were Aspen products.
Aspen’s presence in the Americas is dominated by the businesses in Latin America. Mexico and Brazil are the largest contributors to regional performance. Aspen provides a range of trusted brands across prescription, hospital and over-the-counter (“OTC”) medicines and operates one finished dose form manufacturing facility in Brazil.
The Mexican pharmaceutical market grew 14,0% to USD10,8 billion MAT* June 2021, positively impacted by double-digit growth across the generic and ethical markets.
Pharmaceutical sales across the total Spanish Latin America market grew 20% to USD21,3 billion MAT June 2021.
This region comprises all Asian territories where we sell products, including China. Active trading subsidiaries include those in China, the Philippines, Taiwan and Malaysia with other countries in the region reached via distributors. Sterile Focus Brands are the key contributor to revenue. Our manufacturing facility in India is our primary new product development site.
The Chinese general anaesthesia therapy area consists of inhalation and intravenous products. The propofol market grew 10,6% year-on-year MAT* May 2021.
The South Korean pharmaceutical market is forecast to grow at a CAGR of 6% between 2019 and 2024, reaching Won24,579 billion by 2024.
One of the largest pharmaceutical companies in the Australasia region, with a comprehensive portfolio of medicines comprising Regional Brands, including prescription and over-the-counter products, as well as Sterile Focus Brands. A widely-accredited manufacturing facility is operated in Australia, producing finished dose form (“FDF”) solids, liquids and semi-solids as well as packaging for third party contract manufacturing for domestic and export markets.
The Australian and New Zealand pharmaceutical market combined, grew 1,9% and was valued at AUD20,7 billion MAT* to May 2021.
Europe CIS provides a broad range of Sterile Focus and Regional Brands while operating a range of manufacturing facilities for Aspen’s own production needs, as well as manufacturing for third parties. Sterile Focus Brands comprise anaesthetics and thrombosis in Russia and the other CIS countries only. Manufacturing activities include active pharmaceutical ingredients (“APIs”) and FDF production and our sites are widely accredited. The prefilled syringe and multi-dose form sites in France and Germany respectively, provide FDF medicines for commercialisation by Aspen and third parties for both domestic and export markets.